TarGeT-D: Phase 2 Study of Olutasidenib with Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor IDH1 Mutations
Clinical Trial Grant
Awarded By
Research Institute at Nationwide Children's Hospital
Start Date
April 1, 2026
End Date
March 31, 2031
Awarded By
Research Institute at Nationwide Children's Hospital
Start Date
April 1, 2026
End Date
March 31, 2031